secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2026-08-05T20:09:37+00:00
Accession:  0000939767-26-000096
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q2 2026 revenue $628.7M, GAAP EPS $0.82, non-GAAP EPS $0.91
--------------------------------------------------------------------

- Total revenues $628.7M, up 11% YoY; cabozantinib U.S. net product revenues $573.0M.
- GAAP net income $212.1M ($0.82 diluted EPS) vs $184.8M ($0.65) in Q2 2025.
- Non-GAAP net income $237.1M ($0.91 diluted EPS) vs $212.6M ($0.75) YoY.
- R&D expenses $212.0M, SG&A $147.6M; both up YoY on clinical and marketing costs.
- Zanzalintinib potential launch in metastatic colorectal cancer pending regulatory approval later 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/0000939767-26-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel-20260805.htm
  HTML page:      https://secwatch.observer/filing/0000939767-26-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer